Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 8/20 | 0.40 |
| ▸ | TYK2 | P29597 | 5/20 | 0.38 |
| ▸ | JAK1 | P23458 | 3/20 | 0.38 |
| ▸ | SYK | P43405 | 4/20 | 0.38 |
| ▸ | INSR | P06213 | 2/20 | 0.36 |
| ▸ | IGF1R | P08069 | 2/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26983714 | 0.88 | TYK2 (0.43) | TYK2JAK1JAK2 | |
| SCHEMBL30780374 | 0.88 | TYK2 (0.43) | TYK2JAK1JAK2 | |
| SCHEMBL30780311 | 0.88 | TYK2 (0.46) | MAP4K1TYK2JAK1JAK2 | |
| SCHEMBL26983753 | 0.88 | TYK2 (0.46) | MAP4K1TYK2JAK1JAK2 | |
| SCHEMBL30780454 | 0.82 | TYK2 (0.59) | TYK2JAK1JAK2 | |
| SCHEMBL26983735 | 0.82 | TYK2 (0.59) | TYK2JAK1JAK2 | |
| SCHEMBL30780359 | 0.81 | TYK2 (0.36) | TYK2JAK1JAK2 | |
| SCHEMBL26983745 | 0.80 | TYK2 (0.43) | TYK2JAK1JAK2 | |
| SCHEMBL30780316 | 0.80 | TYK2 (0.43) | TYK2JAK1JAK2 | |
| SCHEMBL24784196 | 0.78 | JAK2 (0.51) | TYK2JAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001898-A1 | Heteroaryl compounds as inhibitors of TYK2/JAK1, composition and application thereof | ACCRO BIOSCIENCE HK LTD (HK) | 2026-01-01 | — | — | US | disclosed |
| EP-4551559-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2/JAK1, COMPOSITION AND APPLICATION THEREOF | Accro Bioscience (HK) Limited (HK) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024010963-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2/JAK1, COMPOSITION AND APPLICATION THEREOF | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2024-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001898-A1 | Heteroaryl compounds as inhibitors of TYK2/JAK1, composition and application thereof | JAK1, JAK2, TYK2 | MAP4K1 1027/4885TYK2 3/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.